Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01181440 · ClinicalTrials.gov registry record · Phase 3

Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers

A Phase 3 study, sponsored by Organogenesis.

Completed
Registry status
Phase 3
Development phase
281
Enrollment target

NCT01181440 is a Phase 3 study that has completed, run by Organogenesis. The registered enrollment target is 281 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01181440, a Phase 3 study, has completed, sponsored by Organogenesis.

COMPLETED
Registry status
Phase 3
Development phase
281 participants
Enrollment target

Study Summary

This study randomly assigns patients with plantar diabetic foot ulcers to receive conventional therapy (debridement, infection control, saline-moistened gauze dressings, and standardized off-weighting) alone or conventional therapy plus Dermagraft(R). Dermagraft is a device containing live human fibroblasts grown on an absorbable polyglactin (Vicryl) mesh. Patients are evaluated weekly until Week 12, then every four weeks until Week 32.

Interventions

  • DEVICE Dermagraft(R)
  • OTHER Conventional care

Trial Details

FieldValue
Enrollment Target 281 participants
Start Date 1994-09
Est. Completion 1997-01
Phase Phase 3

Sponsor

Organogenesis

20 total trials

What the Registry Record Tells You About NCT01181440

The ClinicalTrials.gov registry entry for NCT01181440 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Organogenesis, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dermagraft(R) is the first listed.

NCT01181440 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01181440 about?

NCT01181440 is a clinical study titled "Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers". This study randomly assigns patients with plantar diabetic foot ulcers to receive conventional therapy (debridement, infection control, saline-moistened gauze dressings, and standardized off-weighting) alone or conventional therapy plus Dermagraft(R). Dermagraft is a device containing live human fib...

What is the current status of trial NCT01181440?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 281 participants. The study started on 1994-09. Estimated completion is 1997-01.

What interventions are being tested in trial NCT01181440?

The interventions under investigation include: Dermagraft(R) (DEVICE), Conventional care (OTHER).

Who is sponsoring clinical trial NCT01181440?

This trial is sponsored by Organogenesis, which has 20 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.